MPO’s role in MSA

The myeloperoxidase (MPO) enzyme found in abundant levels in myeloid cells and neutrophils that serves as a a key driver of oxidative and inflammatory processes. MPO levels are significantly increased in activated immune cells (e.g., microglia) in brains from human MSA patients and are thought to promote neurodegeneration. In animal models of MSA, MPO inhibition reduces microglial activation and has neuroprotective effects. MPO inhibition is, therefore, a promising therapeutic strategy for the treatment of MSA.